Exelixis (EXEL) Long-Term Deferred Tax (2018 - 2026)
Exelixis (EXEL) recorded quarterly Long-Term Deferred Tax of $293.7 million in Q2 2026, little changed quarter-over-quarter from $292.6 million in Q1 2026, and down 29.9% on a YoY basis from $419.0 million in Q2 2025.
Exelixis (EXEL) Long-Term Deferred Tax (2018 - 2026) Analysis & Trends
Exelixis' Long-Term Deferred Tax history runs 9 years deep, the most recent figure standing at $293.7 million for Q2 2026.
- In Q2 2026, Long-Term Deferred Tax fell 29.9% year-over-year to $293.7 million; the TTM figure through Apr 2026 stood at $293.7 million (down 29.9% YoY), while the FY2026 annual figure was $292.6 million, down 30.34% from the prior year.
- Long-Term Deferred Tax was $293.7 million for Q2 2026 at Exelixis, roughly flat from $292.6 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $420.0 million in Q1 2025 to a low of $98.0 million in Q2 2022.
- Historically, Long-Term Deferred Tax has averaged $291.6 million across 5 years, with a median of $293.7 million in 2026.
- The sharpest annual moves came in 2022 and 2023: Long-Term Deferred Tax sank 38.98% in 2022, then surged 134.29% in 2023.
- A 5-year view of Long-Term Deferred Tax shows it stood at $231.1 million in 2022, then soared by 56.27% to $361.1 million in 2023, then declined by 0.63% to $358.9 million in 2024, then gained by 16.64% to $418.6 million in 2025, then dropped by 29.83% to $293.7 million in 2026.
- The last three Long-Term Deferred Tax figures came in at $293.7 million (Q2 2026), $292.6 million (Q1 2026), and $418.6 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Exelixis | 13.72 Bn | 12.95 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 293.73 Mn |
| Jan 2, 2026 | 292.58 Mn |
| Oct 3, 2025 | 418.58 Mn |
| Jul 4, 2025 | 419.24 Mn |
| Apr 4, 2025 | 419.05 Mn |
| Jan 3, 2025 | 420.03 Mn |
| Sep 27, 2024 | 358.87 Mn |
| Jun 28, 2024 | 361.56 Mn |
| Mar 29, 2024 | 361.58 Mn |
| Dec 29, 2023 | 361.15 Mn |
| Sep 29, 2023 | 230.99 Mn |
| Jun 30, 2023 | 231.12 Mn |
| Mar 31, 2023 | 229.60 Mn |
| Dec 30, 2022 | 231.11 Mn |
| Sep 30, 2022 | 116.42 Mn |
| Jul 1, 2022 | 113.96 Mn |
| Apr 1, 2022 | 98.00 Mn |
| Dec 31, 2021 | 111.66 Mn |
| Oct 1, 2021 | 125.30 Mn |
| Jul 2, 2021 | 134.67 Mn |